Matthew R. Steensma

Dr. Matthew R. Steensma

Pediatrics | Surgical Oncology
145 Michigan Street Northeast, Suite 5500, 
Grand Rapids, MI 
On Staff At
Accepting New Patients
Offers Telehealth
24 Years of Experience
145 Michigan Street Northeast, Suite 5500, 
Grand Rapids, MI 
OverviewInsuranceLocationsClinical Research

Overview

Matthew Steensma is a Pediatrics specialist and a Surgical Oncologist in Grand Rapids, Michigan. Dr. Steensma has been practicing medicine for over 24 years and is rated as an Experienced provider by MediFind in the treatment of Chondrosarcoma. His top areas of expertise are Fibrosarcoma, Neurofibromatosis, Adult Soft Tissue Sarcoma, Bone Tumor, and Hip Replacement. Dr. Steensma is currently accepting new patients.

His clinical research consists of co-authoring 36 peer reviewed articles and participating in 1 clinical trial. MediFind looks at clinical research from the past 15 years.

Graduate Institution
Wayne State University School Of Medicine, 2002
Residency
Michigan State University
Specialties
Pediatrics
Surgical Oncology
Licenses
Orthopaedic Surgery in MI
Board Certifications
American Board Of Orthopaedic Surgery
Fellowships
Memorial Sloan-Kettering Cancer Center
Hospital Affiliations
Corewell Health Grand Rapids Hospitals
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Locations

Corewell Health Orthopedic Oncology - Lemmen-Holton
145 Michigan Street Northeast, Suite 5500, Grand Rapids, MI 49503

Additional Areas of Focus

Dr. Steensma has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Neurofibromatosis Type 1 (NF1)

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

1 Clinical Trials

Targeting the Mechanisms Underlying Cutaneous Neurofibroma Formation in NF1: A Clinical Translational Approach.
Targeting the Mechanisms Underlying Cutaneous Neurofibroma Formation in NF1: A Clinical Translational Approach.
Enrollment Status: Completed
Publish Date: July 24, 2025
Intervention Type: Procedure

36 Total Publications

Engineering ERα degraders with pleiotropic ubiquitin ligase ligands maximizes therapeutic efficacy by co-opting distinct effector ligases.
Engineering ERα degraders with pleiotropic ubiquitin ligase ligands maximizes therapeutic efficacy by co-opting distinct effector ligases.
Journal: Cell chemical biology
Published: June 07, 2024

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Steensma's expertise for a condition
ConditionClose
    View All 11 Distinguished Conditions
    View All 11 Advanced Conditions
    View All 10 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile